Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...

A statue of a football hero and a tramway set to transform a town which once won "grumpiest town" in the West Midlands and ...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...

The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain ("CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

At the Smith County Commissioners Court meeting, Grassroots America raised concerns over delays and budget issues with road ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Amkor Technology got a $407 million CHIPS Act grant in December. It comes with strings attached, including commitments to ...

US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the ...